BioSpace News Archive

Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that C. Russell Trenary III, President & Chief Executive Officer will participate in the Virtual Investor 2022 Top Picks Conference.

Immix Bio today announced positive interim clinical trial safety data demonstrating 100% completion of IMX-110 planned treatment cycles in its ongoing Phase 1b/2a clinical trial.

Obsidian Therapeutics, Inc. today announced that Maria Fardis , Ph.D., has assumed the role of Chair of Obsidian’s Board of Directors.

Curcumin Extract Shows Positive Results and Pain-Relief Benefits in Knee Osteoarthritis Trial.

X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit people with diseases of the immune system, today announced that management will participate in a fireside chat at B. Riley Securities Oncology Investor Conference.